William Blair Reaffirms “Outperform” Rating for Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals (NASDAQ:AVIR)‘s stock had its “outperform” rating restated by investment analysts at William Blair in a report released on Friday,RTT News reports. William Blair also issued estimates for Atea Pharmaceuticals’ Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.59) EPS and FY2027 earnings at ($1.60) EPS.

Atea Pharmaceuticals Stock Down 0.3 %

NASDAQ:AVIR opened at $2.99 on Friday. Atea Pharmaceuticals has a 12-month low of $2.75 and a 12-month high of $4.18. The firm has a market capitalization of $252.54 million, a price-to-earnings ratio of -1.44 and a beta of 0.18. The stock’s 50 day moving average price is $3.15 and its two-hundred day moving average price is $3.34.

Atea Pharmaceuticals (NASDAQ:AVIR) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Equities research analysts expect that Atea Pharmaceuticals will post -2.01 EPS for the current year.

Insider Transactions at Atea Pharmaceuticals

In other news, Director Franklin M. Berger sold 359,606 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the transaction, the director now owns 451,897 shares in the company, valued at approximately $1,287,906.45. This trade represents a 44.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 17.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BML Capital Management LLC lifted its holdings in shares of Atea Pharmaceuticals by 14.4% during the fourth quarter. BML Capital Management LLC now owns 7,608,312 shares of the company’s stock worth $25,488,000 after buying an additional 958,312 shares in the last quarter. FMR LLC raised its stake in Atea Pharmaceuticals by 2.8% in the 3rd quarter. FMR LLC now owns 6,618,297 shares of the company’s stock worth $22,171,000 after purchasing an additional 182,174 shares in the last quarter. Tang Capital Management LLC raised its stake in Atea Pharmaceuticals by 3.9% in the 4th quarter. Tang Capital Management LLC now owns 4,788,912 shares of the company’s stock worth $16,043,000 after purchasing an additional 181,852 shares in the last quarter. State Street Corp boosted its holdings in Atea Pharmaceuticals by 0.7% in the 3rd quarter. State Street Corp now owns 1,733,486 shares of the company’s stock valued at $5,807,000 after purchasing an additional 11,566 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Atea Pharmaceuticals by 0.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,216,600 shares of the company’s stock worth $4,076,000 after purchasing an additional 9,500 shares in the last quarter. 86.67% of the stock is owned by institutional investors and hedge funds.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.